Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Receivables - Other: 2014-2022

Historic Receivables - Other for Ani Pharmaceuticals (ANIP) over the last 2 years, with Dec 2022 value amounting to $5.0 million.

  • Ani Pharmaceuticals' Receivables - Other was N/A to $5.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $5.0 million, marking a year-over-year change of. This contributed to the annual value of $5.0 million for FY2022, which is N/A change from last year.
  • Per Ani Pharmaceuticals' latest filing, its Receivables - Other stood at $5.0 million for Q4 2022, which was up 4,900.00% from $100,000 recorded in Q3 2020.
  • In the past 5 years, Ani Pharmaceuticals' Receivables - Other ranged from a high of $5.0 million in Q4 2022 and a low of $14,000 during Q3 2018.
  • Its 2-year average for Receivables - Other is $1.3 million, with a median of $100,000 in 2020.
  • Data for Ani Pharmaceuticals' Receivables - Other shows a peak YoY surged of 614.29% (in 2019) over the last 5 years.
  • Over the past 4 years, Ani Pharmaceuticals' Receivables - Other (Quarterly) stood at $100,000 in 2018, then remained steady at $100,000 in 2019, then remained steady at $100,000 in 2020, then reached $5.0 million in 2022.
  • Its Receivables - Other was $5.0 million in Q4 2022, compared to $100,000 in Q3 2020 and $100,000 in Q2 2020.